Last updated on October 2017

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU


Brief description of study

The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU

Clinical Study Identifier: NCT03020992

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

UCB Cares

As0007 101
Brno, Czechia
  Connect »

UCB Cares

As0007 103
Brno, Czechia
  Connect »

UCB Cares

As0007 107
Brno, Czechia
  Connect »

UCB Cares

As0007 108
Ostrava, Czechia
  Connect »

UCB Cares

As0007 109
Pardubice, Czechia
  Connect »

UCB Cares

As0007 102
Praha, Czechia
  Connect »

UCB Cares

As0007 104
Praha, Czechia
  Connect »

UCB Cares

As0007 105
Praha, Czechia
  Connect »

UCB Cares

As0007 304
Frankfurt, Germany
  Connect »

UCB Cares

As0007 301
Freiburg, Germany
  Connect »

UCB Cares

As0007 303
Muenster, Germany
  Connect »

UCB Cares

As0007 302
Munich, Germany
  Connect »

UCB Cares

As0007 401
Amsterdam, Netherlands
  Connect »

UCB Cares

As0007 506
Bialystok, Poland
  Connect »

UCB Cares

As0007 510
Lublin, Poland
  Connect »

UCB Cares

As0007 509
Poznan, Poland
  Connect »

UCB Cares

As0007 511
Poznan, Poland
  Connect »

UCB Cares

As0007 502
Torun, Poland
  Connect »

UCB Cares

As0007 501
Warszawa, Poland
  Connect »

UCB Cares

As0007 505
Warszawa, Poland
  Connect »

UCB Cares

As0007 504
Wroclaw, Poland
  Connect »

UCB Cares

As0007 507
Wroclaw, Poland
  Connect »

UCB Cares

As0007 508
Wroclaw, Poland
  Connect »

UCB Cares

As0007 604
Barcelona, Spain
  Connect »

UCB Cares

As0007 601
Córdoba, Spain
  Connect »

UCB Cares

As0007 603
Madrid, Spain
  Connect »